VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
ONCY
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
ONCYOncolytics Biotech Inc.
$0.44$56M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
HomeStocksONCYCash Flow

Oncolytics Biotech Inc. (ONCY) Cash Flow Statement

27Y historyFree accessUpdated daily

The company faces a critical liquidity inflection point, as evidenced by a quarterly free cash flow deficit of $10.2 million in 2026Q1 and a cash balance that has declined from $34.9 million in 2023Q4 to $5.5 million.

Income StatementBalance SheetCash FlowRatios

ONCY Cash Flow Statement

Annual statement

ONCY Cash Flow Statement

Oncolytics Biotech Inc. (ONCY) cash flow statement — 27-year operating, investing & financing cash flows

AnnualQuarterly
MetricTTMDec'25Dec'24Dec'23Dec'22Dec'21Dec'20Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09Dec'08Dec'07Dec'06Dec'05Dec'04Dec'03Dec'02Dec'01Dec'00Dec'99
Cash from Operations-30.94M-20.11M-19.88M-21.44M-17.21M-22.43M-22.07M-19.91M-11.92M-14.89M-12.48M-15.03M-19.68M-24.44M-34.26M-22.54M-18.03M-16.82M-15.29M-13.57M-12.16M-11.05M-9.22M-5.48M-7.26M-4.27M-3.16M-534.35K
Operating CF Margin %---------------706.08%-------1410.73%-1318.31%-1748.37%-3473.84%--1018.71%-
Operating CF Growth %-109.7%-1.15%7.28%-24.62%23.29%-1.65%-10.86%-66.99%19.95%-19.34%17.01%23.59%19.49%28.65%-51.97%-24.99%-7.21%-10.02%-12.67%-11.63%-9.98%-19.81%-68.41%24.5%-69.81%-35.3%-491%-
Net Income-37.57M-28.76M-22.79M-20.92M-18.3M-26.3M-22.5M-33.12M-17.04M-15.62M-15.14M-13.72M-18.62M-23.53M-36.37M-29.04M-19.97M-17M-17.55M-15.64M-14.3M-12.78M-12.96M-8.54M-6.09M-6.17M-3.61M-574.46K
Depreciation & Amortization-86.06K70K87K303.78K288.83K452K446K485.57K95.38K90.77K162.23K180.41K163.5K131.62K109.28K92.59K63.16K257.25K410.25K1M926.68K855.99K751.75K663.52K574.24K465.45K205.2K1.68K
Stock-Based Compensation4.28M3.1M1.98M1.56M1.75M3.83M2.56M1.47M1.42M578.7K406.08K429.54K980.33K424.38K730.75K1.81M3.25M444.26K64.04K000000000
Deferred Taxes00000000000-1.25M-737.78K-514.11K-640.86K019.97M0-64.04K00000-647.62K-340.57K-126.81K0
Other Non-Cash Items4M4.29M-1.68M-3.72M-1.24M501K-2.78M13.06M-298.56K-124.79K-139.81K429.54K980.33K424.38K730.75K814.91K-19.63M116.02K64.04K539.16K426.32K288.61K3.05M2.89M0000
Working Capital Changes-1.56M1.18M2.52M1.33M288.09K-908K210K-1.8M3.9M180.85K2.23M-1.11M-2.44M-1.37M1.19M3.79M-1.72M-642.27K1.79M530.3K789.15K584.76K-69.06K-486.17K-1.12M1.77M376.77K38.43K
Change in Receivables2.3M2.94M-35K381.43K254.2K-776K1.98M-2.02M4.75M-4.75M285.65K-148.31K-85.9K-60.87K10.41K229.6K-220.2K21.54K-6.24K000000000
Change in Inventory0000000000000000000000000000
Change in Payables-270.16K000000000000000000000000000
Cash from Investing-14.28K-6K-174K15.24M-15.03M-286K-29K-10.9K-107.47K1.98M-51.35K-137.56K-182.79K-287.25K-158.85K1.41M-2.06M4.35M12.54M4.68M11.89M-16.62M-4.5M-16.21M-1.2M-585.51K-372.82K-70.26K
Capital Expenditures-970-6K-174K-6.03K-40.52K-286K-29K-10.9K-107.47K-105.77K-23.53K-108.27K-152.75K-254.83K-126.41K-257.79K-133.53K-9.76K-111.58K-944.72K-35.84K-61.31K-974.04K-1.1M-1.05M-585.51K-48.56K-19.97K
CapEx % of Revenue--------------2.61%------7.83%139.2%350.01%503.77%-15.67%-
Acquisitions000000000000000000-4.68B000000000
Investments----------------------------
Other Investing-13.31K0000000000-29-30.04K-32.42K-320004.68B0-842.61K-1.03M133.61K3M-147.47K0-324.26K-50.29K
Cash from Financing23.21M14.12M5.03M24.12M8.99M33.02M39.77M21.02M13.3M12.81M956.13K23.67M9.04M30.4M20.85M14.82M27.29M38.8M3.46M12.11M241.4K18.78M23.5M16M1.8M2.21M16.6M5.15M
Debt Issued (Net)00-242.48K-306.8K-280.73K-366K-461K-447.5K00019.36M1.21M00000000000000150K
Equity Issued (Net)22.28M14.15M5.03M24.42M9.27M33.38M38.3M18M13.17M12.47M956.13K23.67M9.04M30.22M19.76M026.76M20.04M3.42M12.11M241.4K3.38M17.27M700.88K34K2.21M13.6M3.1M
Dividends Paid0000000000000000000000000000
Share Repurchases0000000000000000000000000000
Other Financing923.11K-27K242.48K0001.94M3.47M124.95K343.44K0-19.36M-1.21M179.24K1.08M14.82M528.21K17.01M41.6K0015.4M6.22M15.3M1.77M03M1.9M
Net Change in Cash-7.81M-5.88M-15.32M17.52M-21.81M10.04M17.07M448.14K1.86M-198.16K-11.98M9.86M-11.07M5.9M-13.6M-6.38M6.85M26.2M714.8K3.22M-19.85K-8.9M9.77M-5.68M-6.65M-2.65M13.07M4.55M
Free Cash Flow-29.08M-20.12M-20.06M-21.45M-17.25M-22.72M-22.1M-19.92M-12.03M-15M-12.5M-15.14M-19.83M-24.7M-34.38M-22.8M-18.17M-16.83M-15.4M-14.51M-12.19M-11.11M-10.2M-6.57M-8.31M-4.86M-3.21M-554.32K
FCF Margin %---------------708.69%-------1418.56%-1457.51%-2098.38%-3977.61%--1034.38%-
FCF Growth %-26.11%-0.3%6.5%-24.36%24.08%-2.81%-10.95%-65.59%19.8%-19.97%17.45%23.63%19.7%28.17%-50.81%-25.49%-7.94%-9.29%-6.1%-19.06%-9.69%-8.97%-55.13%20.87%-71%-51.51%-478.47%-
FCF per Share-0.23-0.21-0.26-0.32-0.30-0.42-0.55-0.90-0.75-1.08-0.99-1.28-2.14-2.81-4.29-3.05-2.76-3.24-3.54-3.41-3.19-3.23-3.39-2.68-3.73-2.50-1.75-0.01
FCF Conversion (FCF/Net Income)0.77x0.70x0.87x1.03x0.94x0.85x0.98x0.44x0.70x0.95x0.82x1.10x1.06x1.04x0.94x0.78x0.90x0.99x0.87x0.87x0.85x0.86x0.71x0.64x1.19x0.69x0.87x0.93x
Interest Paid0000000000000000000000000000
Taxes Paid00128.21K90.46K33.89K35K12K5.45K15.73K136.16K000000000000000000

Key Metrics

Growth RegimeContracting
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Imminent liquidity and dilution

Verified Source

Metrics are mathematically derived from official filings.

SEC 10-K (2026Q1)

Earnings Quality Obscured by Volatility

According to recent financial disclosures, the relationship between net income and operating cash flow remains highly erratic, with the OCF/NI ratio fluctuating from 0.46 in 2025Q3 to 4.16 in 2025Q4, highlighting the significant impact of non-cash adjustments on the company's reported bottom-line performance.

The wide variance in the OCF/NI ratio suggests that net income is a poor proxy for the company's actual cash consumption. Investors should monitor how non-cash items, particularly stock-based compensation, continue to decouple the reported loss from the actual cash burn required to sustain clinical operations.

Persistent Free Cash Flow Deficit

As reported in quarterly filings, the company's free cash flow trajectory remains consistently negative, with a quarterly burn rate that reached $10.2 million in 2026Q1, underscoring the absence of self-sustaining cash generation in this pre-revenue, development-stage biotechnology entity focused on clinical trial advancement.

The persistent negative free cash flow indicates that the company is entirely dependent on external financing to fund its research pipeline. This trajectory appears unsustainable without a significant shift in the clinical milestone timeline or the successful execution of a major partnership agreement.

Working Capital Volatility Impacts Liquidity

Based on the provided cash flow statements, working capital changes have been highly inconsistent, swinging from a $4.3 million inflow in 2024Q3 to a $1.6 million outflow in 2026Q1, which complicates the predictability of the company's short-term liquidity and cash runway management.

These fluctuations likely reflect the timing of clinical trial payments and the settlement of accrued liabilities rather than operational efficiency. The lack of a stable working capital cycle suggests that cash management is reactive to trial-related milestones rather than proactive, increasing the risk of sudden liquidity crunches.

SBC Masks True Operational Burn

Analysis of recent SEC filings reveals that stock-based compensation, which reached $3.2 million in 2026Q1, significantly masks the true economic cost of operations, as these non-cash expenses are added back to reconcile net income to operating cash flow, effectively understating the company's total resource consumption.

While stock-based compensation is a standard tool for talent retention in biotech, its magnitude relative to the total cash burn warrants further investigation. Investors should consider the dilutive impact of these grants alongside the cash burn, as both represent a significant cost to existing shareholders.

ONCY — Frequently Asked Questions

Quick answers to the most common questions about buying ONCY stock.

How much cash does Oncolytics Biotech Inc. (ONCY) generate from operations?

Oncolytics Biotech Inc. (ONCY) generated $-20.1M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.

What is Oncolytics Biotech Inc.'s free cash flow?

Oncolytics Biotech Inc. (ONCY) reported negative free cash flow of $20.1M in 2025, indicating capital requirements exceeded cash from operations.

What is Oncolytics Biotech Inc.'s capital expenditure (CapEx)?

Oncolytics Biotech Inc. (ONCY) spent $0.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.